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Abstract  
Purpose of Review 
A host of immune modulators are now available in clinical practice. The perioperative period is 
characterised by profound alterations in host immunity, which can result in poor outcomes, which include 
infection, cancer recurrence and organ failure. Manipulation of the peri-operative immune response has 
the potential to improve outcomes. A complete understanding of the mechanisms and clinical 
consequences of altered immune function in this setting is therefore imperative.  
Recent findings 
Recent in vivo data has emerged which furthers our understanding of the interaction between tissue 
damage, immune modulation and clinical outcomes by utilising novel laboratory techniques capable of 
monitoring single cell immune signatures. Traditional gene expression assays have continued to 
demonstrate their utility and have been instrumental in defining the host response to perioperative 
allogeneic blood transfusion. These mechanistic studies are complemented by large clinical studies 
describing associations between anaesthetic modalities and immune-related outcomes.  
Summary 
Laboratory techniques are now available that can monitor the perioperative immune response and could 
be further developed to introduce personalised care pathways. Consideration must also be given to 
anaesthesia techniques and perioperative treatments that, whilst not immediately harmful, may be 
associated with poor outcomes temporally distant from the treatment, secondary to induced 
immunosuppression.   
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Introduction 
Tissue damage is inevitable following major surgery and induces a complex host immune response. This 
is initiated by receptor-mediated detection of specific intracellular compounds released by damaged cells. 
These are collectively referred to as alarmins and they induce an inflammatory cascade, the ultimate aim 
of which is tissue repair and the restoration of homeostasis. However, inter-individual variability exists in 
the host response to alarmin release and a dysregulated, poorly coordinated immune response to tissue 
damage is a major contributor to perioperative organ injury and the development of a state of prolonged 
immunoparesis. Perioperative large-scale alterations in immune and inflammatory pathways are 
associated with many clinically important post-operative complications, which include infections, renal 
injury and cancer recurrence. In addition to tissue damage, many additional factors influence the 
perioperative host immune response. These include the administration of anaesthetic agents, regional 
anaesthesia, analgesics, anti-emetics, blood products and the underlying disease process. This review will 
discuss recent advances in our understanding of this response, potential triggers and the clinical 
consequences of altered perioperative immunity.    
 
The immune response to major tissue damage  
The immune response to major tissue damage has been extensively characterised [1*]. Although severe 
traumatic injury as a model provides information that is highly relevant and applicable to perioperative 
medicine, the picture is clouded by confounding influences such as hypoperfusion and the subsequent 
reperfusion injury, the frequent transfusion of allogenic blood products and neuro-inflammatory mediated 
changes secondary to an often coexisting traumatic brain injury [1*]. The key link between tissue damage 
and subsequent inflammation is the release of alarmins [2].  
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Alarmins, often termed Damage-Associated Molecular Pattern molecules (DAMPs), are a group of 
structurally diverse compounds released following tissue damage as cells undergo physiological stress or 
necrosis [3]. DAMPs are the endogenous equivalent of Pathogen Associated Molecular Pattern molecules 
(PAMPs) that initiate an immune response in the setting of infection.  Indeed, DAMPs such as high-
mobility-group box (HMGB) 1 and mitochondrial DNA (mtDNA) bear significant structural homology to 
their PAMP analogues and often activate the same pattern recognition receptors (PRRs) [3, 4]. This, in 
part, explains why the clinical pictures of severe sterile inflammation and sepsis can be difficult or 
impossible to distinguish. A wide variety of PRRs have been described including the membrane bound 
Toll-like receptors (TLRs) and the cytoplasmic NOD-like receptors (NLRs) [3, 5]. Activation of PRRs 
induces an enzymatic cascade, which results in down-stream phosphorylation of transcription factors such 
as NF-κB, which in turn alters cytokine transcription (Figure 1). Immune cell subtypes are activated 
dependent on their expression of specific PRRs on their cell surface at the time of alarmin release [5]. 
Alarmins not only activate this innate response but also provide a vital link between the innate and 
adaptive immune systems by activating antigen-presenting cells such as monocytes and dendritic cells [6].  
Until quite recently, studies exploring the inflammatory response to major tissue damage have been 
mainly limited to a reductionist approach where correlations have been sought between clinical end points 
and a limited number of candidate mediators. The success of this approach has varied depending on the 
end point chosen and the assay methodology, with quantitative polymerase chain reaction (qPCR) 
quantification of messenger RNA (mRNA) transcripts proving more sensitive than enzyme linked 
immunosorbant assays (ELISA) quantification of protein product. Levels of interleukin 6 (IL-6) and IL-
10 consistently rise in proportion to the extent of the tissue damage and levels are associated with a 
greater incidence of subsequent nosocomial infection [7-10]. As arguably the most potent anti-
inflammatory cytokine it is unsurprising that high IL-10 levels are associated with later infection. 
However, although IL-6 is traditionally considered a pro-inflammatory cytokine it also up-regulates 
suppressor of cytokine signalling (SOCS)-1 expression and inhibits T helper cell type 1 (Th1) 
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differentiation [11]. In this manner, IL-6 could plausibly exert an effect that limits effective host 
bactericidal capacity. Similarly, the expression of Human Leukocyte Antigen DR on the surface of 
monocytes (mHLA-DR) consistently falls following tissue damage and is related to nosocomial infection 
[12, 13]. Again this is unsurprising as the maintenance of adequate Major Histocompatibility Complex 
(MHC) class ΙΙ molecules such as HLA-DR on the surface of antigen presenting cells is crucial to 
maintain immune competence. Others have proposed genomic signatures where higher ratios of anti-
inflammatory to pro-inflammatory cytokines correlate with postoperative infection [14]. What remains 
elusive is the mechanism whereby alarmin release and the subsequent enzymatic cascades lead to an 
immunosuppressed phenotype and the survival advantage, if any, of this trait.  
Advances in technology recently permitted the simultaneous analysis of the leukocyte transcriptome of 
20,720 genes in patients following severe blunt trauma and burn injury in a landmark paper [15]. 
Following these stimuli, which would clearly result in significant alarmin release, 80% of cellular 
pathways and functions were altered. Innate immunity pathways, B-cell receptor signalling and IL-10 
signalling all demonstrated up-regulated gene expression whereas antigen presentation and T-cell 
activation were down-regulated. Importantly, it was the overall magnitude of the genomic alterations that 
correlated with nosocomial infections and organ impairment as opposed to differential activation of 
specific pathways. Although this snapshot of the transcriptome was within 12 hours of injury, in some 
cases patients had undergone extensive resuscitation and therefore this heterogeneous picture should be 
interpreted with caution in the context of the perioperative patient. This paper has however helped to re-
define the previously proposed bimodal inflammatory response model to tissue damage, suggesting 
concomitant activation of pro-inflammatory and anti-inflammatory pathways. 
Further application of advanced technology has seen investigators utilise mass cytometry to detect 
surgery-induced immune perturbations in clinical samples and relate these findings to post-operative 
recovery [16**]. Mass cytometry involves using antibodies to tag cellular components prior to nebulising 
the cells and then using a time of flight mass spectrometer for analysis. This complex technique has 
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extensively described the immune response in peripheral blood following elective hip arthroplasty and 
has demonstrated a time-dependent and cell type specific activation of immune signalling networks. Over 
the early post-operative period there is an expansion of Natural Killer (NK) cells, neutrophils and CD14+ 
monocytes, which is followed, within 24 hours, by contraction of CD4+ and CD8+ T cells. Most notable 
was a six-fold expansion of CD33+CD11b+CD14+HLA-DRlow monocytes with phenotypic similarities to 
myeloid derived suppressor cells (MDSCs). MDSCs are a heterogeneous group of immunosuppressive 
cells [17] that remain poorly defined in terms of cell surface markers and directly suppress T cell 
functions through a variety of mechanisms including the production of reactive oxygen species (ROS) 
[18] and Arginase-1 [19] as well as IL-10 and TGF-β release [20]. In addition to the monocyte derived 
MDSCs that expand following hip arthroplasty, a distinct subset of CD62Ldim neutrophil-derived MDSCs 
appear shortly after blunt trauma and tissue injury and induce T cell suppression in a Mac-1 (CD11b) 
dependent fashion [21, 22]. Further characterisation of the expansion of MDSCs in the post-operative 
period may provide a vital link between alarmin release and an immunosuppressed phenotype.  An 
analysis of surgery induced changes in the phosphorylation of intracellular signalling proteins in different 
immune subsets provides interesting correlations, particularly in the CD14+HLA-DRlow monocyte clusters 
where immune correlates, such as STAT3 signalling, account for up to 60% of the variability in post-
operative recovery [16]. It is particularly relevant that in another cohort pre-operative differences in 
monocyte STAT signalling pathways correlate to post-operative complications [23*]. 
These data demonstrate that our understanding of the immune response to surgery and tissue damage is 
rapidly expanding in tandem with available technology and provides opportunities for the identification of 
therapeutic targets and predictive biomarkers. 
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Anaesthesia, analgesics & the inflammatory response 
Whilst the presence of significant tissue damage exerts the dominant influence on altered perioperative 
immunity, the administration of anaesthetic agents has additional and complex effects. In the clinical 
scenario it can be very difficult to confidently separate the immune modulating effects of anaesthesia 
from the response to surgery and tissue damage and consequently much of the available mechanistic data 
is generated either from in vitro experimental work or animal models. Broadly speaking, the overriding 
effect of anaesthesia on the immune system is one of suppression and is mediated both directly and 
indirectly. Inhalational and intravenous anaesthetics induce lymphocyte apoptosis and impair neutrophil 
phagocytosis [24]. Secondary immunosuppressive effects are mediated through modulation of the neural 
immune-regulatory circuit and activation of cholinergic anti-inflammatory pathways and also as a 
consequence of altered adrenocortical functions [25]. Opioids are administered frequently during 
anaesthesia and their inhibition of innate and adaptive immunity is well described [26]. Natural killer 
cells, a key facet of innate immunity and host tumour surveillance, are suppressed by both anaesthesia and 
opioids [27]. Clearly, the choice of anaesthetic technique may have important clinical implications 
independent of the surgical procedure. The presence of an anaesthesia-induced immunocompromised 
phenotype may affect outcome in different ways but in the perioperative setting it is the creation of a pro-
tumour and pro-infection cytokine and inflammatory milieu that is of key concern. Cancer and infection 
are intimately linked as both flourish in an environment of T cell exhaustion and lymphocyte anergy, such 
as is observed in the perioperative period [28*]. It is also notable that both conditions themselves also 
induce this phenotype, which has additional implications for those patients with chronic infections and 
malignancies that undergo operative treatment.     
Although the hormonal stress response is not completed ablated by the use of regional anaesthesia, 
avoiding general anaesthesia is associated with a blunted response and lower peak levels of serum cortisol 
[29]. Interestingly, in a large cohort of patients undergoing knee arthroplasty the administration of 
neuraxial anaesthesia alone when compared to general anaesthesia alone was associated with a decreased 
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incidence of post-operative infections [30].  The odds of pneumonia occurrence were 0.51 in those 
patients receiving neuraxial anaesthesia alone when compared to general anaesthesia alone in this cohort. 
Whilst this study was not randomised it is important that the association remained following a propensity-
matched analysis. A strategy of limiting, but not excluding, inhalational and intravenous anaesthetics by 
combining epidural and general anaesthesia has suggested subtle advantages above general anaesthesia 
alone in terms of the duration of post-operative immunosuppression, reduction in absolute T lymphocyte 
count and the relative proportions of Th1, Th2 and Treg cell subsets [31, 32]. However, the clinical benefit 
of this combined approach remains unclear. A meta-analysis of studies comparing a technique of 
combined epidural and general anaesthesia versus general anaesthesia alone failed to convincingly 
demonstrate a benefit in terms of cancer recurrence [33]. However, in a review of nearly 400,000 patients 
undergoing hip or knee arthroplasty, whilst the benefit of neuraxial anaesthesia alone was replicated in 
terms of lesser infection risk any protective effect appeared markedly reduced in the cohort that received a 
combined general and regional anaesthesia technique [34]. In each of the above studies the absence of 
randomisation makes interpretation difficult. Consequently, these studies are prone to inherent biases 
making it impossible to draw definitive conclusions and they should be viewed as hypothesis generating. 
This viewpoint is supported by a recent consensus statement expressing concern that experimental 
evidence suggests a link between anaesthestic technique and cancer recurrence yet accepts that there is 
insufficient clinical evidence to justify any change in practice and calls for the conduct of definitive 
randomised clinical trials [35]. 
 
Common adjunctive perioperative treatments & inflammation  
Dexamethasone is frequently administered during anaesthesia as an effective prophylactic anti-emetic. 
Single doses have additional beneficial effects such as enhanced analgesia and reduced surgical site 
swelling. However, it is a potent glucocorticoid and even single doses can display effects on 
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adrenocortical functions a number of days following administration [36]. Although there is clear 
physiological rationale for implicating dexamethasone in enhancing the risk of postoperative infection the 
clinical data have been conflicting [37-39]. A recent meta-analysis of randomised controlled trials using 
single-dose dexamethasone found no association with post-operative infection [40]. These results should 
however be interpreted cautiously as the dexamethasone group also received less opioids, thereby 
introducing a potential source of bias. 
Other ubiquitously prescribed perioperative treatments with potential immunomodulating properties, such 
as paracetamol, NSAIDs and gabapentinoids, have not demonstrated clear associations with important 
immune outcomes such as infection [41].   
The immunomodulating qualities of perioperative allogenic blood transfusion have long been appreciated 
and have even been exploited to prevent renal allograft rejection in the era prior to the development of 
effective immunosuppressants [42]. The unintended clinical consequences of perioperative immune 
modulation by allogeneic blood, particularly following colorectal surgery, include an increased 
susceptibility to infectious complications and also cancer recurrence [43-45]. More recently, similar links 
between transfusion and cancer recurrence have also been reported following surgery for prostate, 
hepatic, and head-and-neck cancers [46-48]. Progress towards identifying a plausible mechanism has been 
made by our group’s identification of a pattern of gene expression, consistent with immunosuppression, 
associated with blood transfusion in two separate cohorts of patients; those undergoing major elective 
gastrointestinal surgery and also following severe traumatic injury [49*, 50*]. The observed pattern of 
cytokine production could classically be described as both a pro-infection and pro-tumour environment 
and indeed in the trauma cohort an association was also observed between blood transfusion and 
infectious complications [50*]. Interestingly, blood stored for prolonged periods prior to administration 
may be particularly deleterious with in vivo models suggesting that aged red blood cells may exert 
enhanced tumour progression [51]. Our group has also recently demonstrated that the severity of post-
traumatic immunosuppression is related to the duration of storage blood products thereby suggesting a 
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mechanistic link [52]. These data support the hypothesis that aged red blood cells may promote tumour 
recurrence and increase susceptibility to infectious complications through modulation of the immune 
system. 
 
Epigenetics and immune responsiveness 
Epigenetics is an umbrella term that describes host mechanisms of altering gene expression that do not 
require a change in the underlying DNA sequence. The enzymatic conversion of cytosine to 5-
methylcytosine and the methylation or acetylation of chromatin usually causes transcriptional repression 
by impeding access to promoter regions whereas the overexpression of micro RNAs (miRs) can both 
inhibit transcription and target messenger RNA (mRNA) for degradation.  Cancer research has pioneered 
the study of epigenetic modifications that promote an immunosuppressed phenotype thereby facilitating 
immune evasion by cancerous cells and has also been at the forefront of developing epigenetic modifying 
agents that can target these processes [53*]. In the perioperative period epigenetic studies have largely 
focused on acute and chronic pain processes, although data supportive of a key role in inflammation and 
immunosuppression have emerged [54]. For example, the use of opioids in the perioperative period 
promotes global DNA methylation in peripheral blood leukocytes [55]. This is consistent with the 
transcriptional repression of pro-inflammatory genes, which may have longer-term implications as 
epigenetic alterations persist. Furthermore, our group have described the post-traumatic production of 
miRNAs with sequence complementarity to the mRNA transcripts of key cytokines whose expression 
levels change markedly following tissue damage [56]. This may represent an epigenetic regulation of the 
response to tissue damage through the targeted degradation of pro-inflammatory mRNAs by miRs. In this 
setting miR levels also correlate with nosocomial pneumonia. Although the study of epigenetics in the 
perioperative period is in its infancy the therapeutic and diagnostic implications may be substantial.     
 
	   11	  
Conclusions 
Rapid advances in our understanding of perioperative inflammatory processes, their causes and 
consequences coincides with development of multiple, clinically applicable immune and epigenetic 
modulators such as growth factors, antibodies, DNA hypomethylating agents, histone deacetylase 
inhibitors and micro RNA mimics. The prospect of manipulating an errant immune response to major 
surgery is no longer aspirational. Personalised medicine has become a reality for many patients suffering 
from a variety of immune related disorders such as myelodysplasia, rheumatoid arthritis and 
inflammatory bowel disease. These patients now routinely benefit from therapies that target specific 
facets of a pathological immune response and the challenge for perioperative medicine is to distinguish 
between protective and pathogenic immune responses in the perioperative period and to identify 
modifiable immune pathways that when altered can impact on important clinical endpoints. 
Uniquely, the elective nature of the majority of surgical procedures introduces the possibility of 
developing a pre-emptive, preventative, immunotherapy strategy that may ultimately prove advantageous. 
The potential for pre-emptive or early therapies for those undergoing scheduled procedures vastly 
increases the prospects of success of any intervention for the perioperative patient. To achieve this 
ultimate aim basic scientists must continue to define pathological inflammatory pathways and collaborate 
with translational scientists identifying interventions suitable for clinical use. Clinical trialists must also 
be engaged with this process so that potential patient benefits are revealed in well-designed clinical trials. 
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Key Points 
 
1. The immunological response to tissue damage is broad but predominately 
immunosuppressive in nature. 
2. Anaesthetic technique plays a key role in modulating the immune response, with 
neuraxial anaesthesia potentially reducing the incidence of nocosomial infections 
through the avoidance of general anaesthetic agents. 
3. The role of allogeneic blood transfusion augments the immune response seen to 
tissue damage. 
4. Laboratory techniques are now available that can monitor the perioperative 
immune response and could be further developed to introduce personalised care 
pathways to manipulate an errant immune response.  
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Legend 
Fig. 1: Pathways of immune activation following tissue damage 
Tissue damage leads to the release of Damage Activated Molecular Patterns (DAMPs) into the 
circulation, in this case illustrated by high-mobility-group box (HMGB) 1 and mitochondrial DNA 
(mtDNA), causing activation of pattern recognition receptors (PRRs). DAMPs also independently 
activate neutrophils, monocytes and dendritic cells.  
Activation of PRRs causes the triggering of signalling pathways and transcription factors such as NF-kB. 
NF-kB then translocates to the nucleus, promoting cytokine gene transcription. Protein translation results 
in the secretion of cytokines and chemokines.  
Postoperatively, increases in neutrophils, monocytes and natural killer (NK) cells are seen along with later 
decreases in CD4+ and CD8+ T-cells. IL-6 and IL-10 consistently increase during this phase and IL-10 is 
associated with downregulation of HLA-DR expression on the surface of circulating monocytes. 
Immunosuppressive Treg cells and myeloid derived suppressor cells (MDSCs) increase postoperatively. 
MDSCs cause T-cells suppression via the secretion of reactive oxygen species (ROS), arginine-1 as well 
as the immunosuppressive cytokines, IL-10 and TGF-β, amongst other mechanisms. Treg cells are known 
producers immunosuppressive cytokines; IL-10, TGF-β and IL-4. 
The transfusion of blood and blood products is known to contribute to this immunosuppressive 
environment, while anaesthetics and opioids cause increase T-cell apoptosis, impair neutrophil 
phagocytosis and suppress NK cells suppression. Anaesthetics mediate secondary effects through altered 
adrenocortical function and central mechanisms. 
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